Clinical Trials Logo

Clinical Trial Summary

To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.


Clinical Trial Description

This is a pilot, open-labelled, to determine if oral administration of a single dose of ergocalciferol lowers plasma mucin-1 levels. The study population will include 40 healthy individuals and 40 individuals with ADTKD-MUC1. The study consists of an initial screening, signing of consent of interested individuals, performance of pregnancy test in women of child-bearing age and screening labs, and administration of 200,000 units of ergocalciferol on Day 0 (On Study). Laboratory studies will be performed at baseline, on Days 3, 7, and 10. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03747523
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Completed
Phase Early Phase 1
Start date March 12, 2019
Completion date January 27, 2020

See also
  Status Clinical Trial Phase
Withdrawn NCT03073369 - Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease Phase 4